Mohammadparsa Khakpour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammadparsa Khakpour has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Marie-Ève Tremblay
School of Medical Sciences, Faculty of Health, University of Victoria, Victoria, BC, Canada
2 shared publications - Adrian Hayday
Francis Crick Institute, London, UK
1 shared publication - Annabel Borg
The Francis Crick Institute, London, UK
1 shared publication - Antonia Landwehr
School of Medical Sciences, Faculty of Health University of Victoria Victoria British Columbia Canada
1 shared publication - Carola G. Vinuesa
Francis Crick Institute, London, UK
1 shared publication - Elly M. Hol
Department of Translational Neuroscience, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
1 shared publication
Latest Publications
- 25 September 2026
- Published by Springer Nature
- p. 101-137
Ultrastructure of Glial Cells in iPSC-Derived Unguided Neural Organoids from APOE4/4 Patients with Alzheimer’s Disease
- 25 September 2026
- Published by Springer Nature
- p. 101-137
Ultrastructure of Glial Cells in iPSC-Derived Unguided Neural Organoids from APOE4/4 Patients with Alzheimer’s Disease
- Open Access
The antipsychotic drug clozapine suppresses autoimmunity driving psychosis-like behavior in mice
Antipsychotic drugs are the first-line treatment for psychosis yet their mechanism of action remains poorly understood, largely due to the challenge to faithfully model psychosis preclinically. Here, we focus on the emerging concept that psychosis can be caused by brain autoimmunity and present a novel mouse model of anti-N-methyl-D-aspartate-receptor (anti-NMDAR) encephalitis, a condition that manifests with psychosis and autoantibodies against the NMDAR. We devised a new mRNA-based approach to immunize mice against the NMDAR. Immunized mice developed psychosis-like behaviors that were caused by anti-NMDAR autoantibodies leading to phagocytosis of NMDARs by brain micro-glia. The antipsychotic drug clozapine rescued psychosis-like behaviors and, remarkably, reduced anti-NMDAR autoantibody levels and antibody-mediated phagocytosis of NMDARs. The immunomodulato-ry effects of clozapine were confirmed in a mouse model of systemic lupus erythematosus. Our results demonstrate that clozapine suppresses autoimmunity driving psychosis-like behaviors, raising the possibility that immunomodulation contributes to antipsychotic drug action.
Open AccessThe antipsychotic drug clozapine suppresses autoimmunity driving psychosis-like behavior in mice
Antipsychotic drugs are the first-line treatment for psychosis yet their mechanism of action remains poorly understood, largely due to the challenge to faithfully model psychosis preclinically. Here, we focus on the emerging concept that psychosis can be caused by brain autoimmunity and present a novel mouse model of anti-N-methyl-D-aspartate-receptor (anti-NMDAR) encephalitis, a condition that manifests with psychosis and autoantibodies against the NMDAR. We devised a new mRNA-based approach to immunize mice against the NMDAR. Immunized mice developed psychosis-like behaviors that were caused by anti-NMDAR autoantibodies leading to phagocytosis of NMDARs by brain micro-glia. The antipsychotic drug clozapine rescued psychosis-like behaviors and, remarkably, reduced anti-NMDAR autoantibody levels and antibody-mediated phagocytosis of NMDARs. The immunomodulato-ry effects of clozapine were confirmed in a mouse model of systemic lupus erythematosus. Our results demonstrate that clozapine suppresses autoimmunity driving psychosis-like behaviors, raising the possibility that immunomodulation contributes to antipsychotic drug action.